Oncology NEWS International Vol 14 No 10

SLNM May Reduce Colon Ca Recurrences by Upstaging Patients Who May Then Receive Adjuvant Chemotherapy

October 01, 2005

ORLANDO-Sentinel lymph node mapping (SLNM) upstaged nodal metastases in 15% of colon cancer patients in a single-institution retrospective study of more than 300 colon cancer patients at stages T1 to T4. Routine pathological examination after conventional surgery understages 15% to 20% of colorectal cancer patients, the researchers said. Thus, SLNM has a potential survival benefit: "Higher numbers of patients with nodal metastases in the group that underwent SLNM went on to receive chemotherapy," they reported. "This may explain the reduced recurrence rates seen in these patients, which may lead to prolonged survival."

EUS-FNA + Mediastinoscopy Boosts Staging in NSCLC

October 01, 2005

LEIDEN, The Netherlands-In a prospective 100-patient study that may have direct applicability to clinical practice, a team of Dutch researchers has demonstrated improved identification of mediastinal tumor invasion (T4) or lymph node metastases (N2/N3) in patients with non-small-cell lung cancer (NSCLC) when preoperative staging employed transesophageal ultrasound–guided fine-needle aspiration (EUS-FNA) in addition to mediastinoscopy. The finding, they said, is attributable to the "complementary reach" of these diagnostic tools in assessing regional lymph node stations and in the ability of EUS-FNA to detect mediastinal tumor invasion.

Digital Mammography More Accurate in Younger Women

October 01, 2005

ARLINGTON, Virginia-Data from more than 40,000 women who underwent both digital and film mammography at 33 sites in the US and Canada show that, while the techniques have similar overall diagnostic accuracy in breast cancer screening, digital mammography is more accurate in women under the age of 50 years, women with radiographically dense breasts, and pre- or perimenopausal women.

Taxotere/Herceptin Ups DFS in Early-Stage HER2+ Breast Ca

October 01, 2005

EDMONTON, Canada-Two docetaxel (Taxotere)-based chemotherapy regimens in combination with the monoclonal antibody trastuzumab (Herceptin) given after surgery significantly improved disease-free survival (DFS) in women with early-stage HER2-positive breast cancer, according to interim results of a phase III trial announced by the Breast Cancer International Research Group (BCIRG) and Sanofi-Aventis. The BCIRG 006 trial compared a standard treatment arm of four cycles of doxorubicin (Adriamycin) and cyclophosphamide followed by docetaxel (AC-T) with two trastuzumab-containing regimens: AC-T plus trastuzumab (AC-TH) and docetaxel plus carboplatin plus 1 year of trastuzumab (TCH) given concomitantly with chemotherapy.

FOLFOX4 + Avastin Ups Survival in Colorectal Ca

October 01, 2005

ORLANDO-Adding high-dose bevacizumab (Avastin) to FOLFOX4 improves overall survival, progression-free survival (PFS), and response in previously treated patients who have advanced colorectal cancer, Bruce J. Giantonio, MD, reported at the 41st Annual Meeting of the American Society of Clinical Oncology (abstract 2). Dr. Giantonio, of the University of Pennsylvania, presented results of the Eastern Cooperative Oncology Group (ECOG) E3200 study.